Zag Bio^™ Launches with $80 Million Financing to Advance Thymus-Targeted Medicines for Autoimmune Diseases

Zag Bio^™, Inc. announced the company’s launch. Zag Bio has discovered a novel approach to deliver tolerizing antigens to the thymus to achieve durable antigen-specific central tolerance to treat autoimmune disease.